123 ManiS.SwargiaryG.SinghK
completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients
A successful card swipe at a pharmacy or telehealth checkout does not prove your plan will accept the charge some employer plans have warned members that GLP-1 transactions may process at the register but still get clawed back later if the plan excludes weight-loss use
Recently, compounded medications have made their way to the GLP1 market
Bioactive sphingolipids especially ceramide (Cer), sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), and others [7], play pivotal roles in various biological processes including cell differentiation, proliferation, apoptosis, and migration [8]
Now, how I'm going to address all of this